S kin cancers affect more than half of organ-transplant recipients during their long-term course. 1 Several studies have shown that after a first cutaneous squamous-cell carcinoma, multiple subsequent skin cancers develop in 60 to 80% of kidney-transplant recipients within 3 years. 2, 3 Transplant recipients share common risk factors with the nonimmunosuppressed population, 4 but the specific tumor burden of such patients is linked to the immunosuppressive medications used. 5, 6 A decrease in cutaneous carcinogenesis after the reduction of immunosuppression has been reported. 7 Consequently, changes in immunosuppression are frequently made in patients with skin cancer, although there is currently no consensus on the level of morbidity at which this decision is justified. 8 Cutaneous squamous-cell carcinoma appears to be one of the most appropriate markers for initiating a change in immunosuppressive medication for organ-transplant recipients and subsequently for assessing the effect of such changes on carcinogenesis according to skin-tumor counts.
Skin cancers result from both a decrease in immunosurveillance and drug-specific properties. Calcineurin inhibitors (cyclosporine and tacrolimus) may enhance tumor development through mechanisms independent of host immunity. [9] [10] [11] [12] In contrast, inhibitors of the mammalian target of rapamycin (mTOR), including sirolimus (Rapamune, Pfizer) and everolimus, are newer immunosuppressants that have antineoplastic properties. 13, 14 A few studies have reported a lower rate of skin cancer in transplant recipients who were treated with sirolimus than in those treated with calcineurin inhibitors (with either first-time therapy 15, 16 or after switching 17, 18 ), but data focusing on the effect of sirolimus on skin carcinomas are still limited. 19, 20 The aim of our study, called the Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients (TUMORAPA), was to assess, in a large cohort, the efficacy of sirolimus for the secondary prevention of skin cancers in kidney-transplant recipients receiving calcineurin inhibitors.
Me thods

Eligibility
Kidney-transplant recipients with stable kidney function who were receiving calcineurin inhibitors and had at least one invasive post-transplant cutaneous squamous-cell carcinoma after transplantation were eligible to participate. (Patients with in situ lesions, such as Bowen's disease and premalignant keratosis, or metastatic cutaneous squamous-cell carcinomas were not considered.) The major exclusion criteria were multiorgan transplantations, a history of organ rejection during the past 6 months, poor graft function (estimated glomerular filtration rate, <30 ml per minute, according to the Cockcroft-Gault formula; or 24-hour protein excretion of >1 g), uncontrolled hyperlipidemia, hematologic or hepatic disorders, and retinoid treatment. The limits on baseline immunosuppressant doses were as follows: glucocorticoids, 10 mg or less per day; azathioprine, 1 mg or less per kilogram of body weight per day; mycophenolate mofetil, 1.5 g or less per day; and target cyclosporine and tacrolimus blood trough levels, 75 to 125 ng per milliliter and 4 to 7 ng per milliliter, respectively.
Trial Design
This phase 3, multicenter, randomized, open-label trial included patients who had had a first cutaneous squamous-cell carcinoma (TUMORAPA-1, which was registered under ClinicalTrials. All patients received a detailed description of the study and provided written informed consent. The full study protocol, including the statistical analysis plan, is available with the full text of this article at NEJM.org.
Randomization and Treatment
Patients were randomly assigned in a 1:1 ratio either to transition to sirolimus from calcineurin inhibitors or to continue receiving calcineurin inhibitors. In the sirolimus group, calcineurin inhibitors were discontinued and sirolimus was added to the usual immunosuppressive agents, according to the routine practice of each center (target trough level of sirolimus, 6 to 12 ng per milliliter). The conversion to sirolimus was considered n engl j med 367;4 nejm.org july 26, 2012 331 to be rapid if calcineurin inhibitors were discontinued within 7 days and progressive if the conversion took longer than 7 days. In the calcineurininhibitor group, cyclosporine and tacrolimus were maintained at their previous target trough levels.
Study Evaluations
All patients were examined by a dermatologist and a nephrologist at enrollment and every 3 months thereafter until the 2-year mark. During the dermatologic examination, investigators recorded skin type according to Fitzpatrick's classification (Table 1 in the Supplementary Appendix, available at NEJM.org), eye and hair color, and sun exposure. Sun exposure was scored on the basis of occupational and leisure exposure (1, low; 2, medium; and 3, high), tanning-bed use (1, never; 2, occasional; and 3, regular), and residence of more than 6 months in a tropical area (1, no; and 2, yes). All histologically determined skin tumors (including squamous-and basal-cell carcinoma, keratoacanthoma, Bowen's disease, premalignant keratosis, and other rare cancers) before and after randomization were counted. Sun-protection advice was provided and its importance was emphasized.
During visits to the nephrology or transplantation clinic at each center, doses of immunosuppressive medications were recorded, along with the patient's history of acute organ rejection. For patients who had undergone more than one transplantation, the duration of immunosuppression was calculated by summing the number of months of receipt of immunosuppressive drugs from the first transplantation and subtracting the intervening duration of dialysis. At the initial nephrology visit, measurements of serum creatinine levels, 24-hour protein excretion, and sirolimus or calcineurin-inhibitor levels were obtained; these measurements were then repeated every 3 months in the calcineurin-inhibitor group. In the sirolimus group, monitoring was carried out weekly during the first 2 weeks, monthly during the first 3 months, and then every 3 months.
End Points
The primary end point was survival free of new cutaneous squamous-cell carcinoma at 2 years.
Secondary end points included the time until the onset of new cutaneous squamous-cell carcinoma, occurrence of other skin and nonskin tumors, and graft function. Safety was monitored by means of physical examination, the recording of adverse events, and changes in laboratory measurements.
Study Oversight
The manufacturer of sirolimus, Pfizer (formerly Wyeth), provided a research grant but had no role in the trial design or in the collection, analysis, or interpretation of the data or writing of the report. The study was sponsored by the Hospices Civils de Lyon, and grants were received from the French Ministry of Health, the French Society of Interval between diagnosis of the most recent cutaneous squamous-cell carcinoma and randomization -mo Dermatology, and Pfizer. The first and last authors, along with several colleagues, made the decision to submit the manuscript for publication and vouch for the accuracy and completeness of the data and the fidelity of the study to the protocol.
Statistical Analysis
Since we used the same methods and end points that were used in both TUMORAPA-1 and TUMORAPA-N, the data were pooled. The analysis included the total population as well as separate analyses of patients who had had a single cutaneous squamous-cell carcinoma and those who had had more than one such lesion before randomization. We used the Mann-Whitney test for comparing quantitative variables and Fisher's exact test for comparing qualitative variables. The main evaluation criteria were analyzed in the intention-to-treat population. We evaluated the status at 2 years for patients who had withdrawn from the study. Deceased patients without cutaneous squamous-cell carcinoma before death were included among patients who were free of cutaneous squamous-cell carcinoma.
Patients were analyzed according to the randomization scheme. We used nonparametric maximum-likelihood estimation to analyze the rate of survival free of new cutaneous squamouscell carcinoma on the basis of interval-censored data. 21 Since the occurrence of a new carcinoma was observed only quarterly because of the timing of visits, the actual time of the event was unknown and survival was computed at time intervals rather than at a precise times (i.e., the interval between the last visit at which no diagnosis of cutaneous squamous-cell carcinoma was made and the visit when the cutaneous squamous-cell carcinoma was first mentioned). We used the generalized log-rank test to compare the two study groups. 21 Crude hazard ratios, adjusted haz- * There were no significant differences between the two study groups. Percentages may not total 100 because of rounding.
To convert the values for creatinine to milligrams per deciliter, divide by 88.4. † Skin type was graded according to Fitzpatrick's classification as follows: type I, white with history of always burning and never tanning; type II, white with some burning and tanning with difficulty; type III, beige with occasional burning and gradual tanning to light brown; and type IV, beige with rare burning and tanning to moderate brown. ‡ Sun exposure was scored on the basis of occupational and leisure exposure (1, low; 2, medium; and 3, high), tanning-bed use (1, never; 2, occasional; and 3, regular), and residence of more than 6 months in a tropical area (1, no; and 2, yes). § The estimated glomerular filtration rate was calculated by means of the Cockcroft-Gault formula.
The ard ratios, and tests for interaction were obtained with the use of an accelerated failure-time model with interval censoring. In order to assess the benefit-risk balance, we counted the numbers of cutaneous squamous-cell carcinomas and treatment-related serious adverse events during the therapy period and for 3 months after the discontinuation of treatment. We performed secondary evaluations of patients who completed the 2-year treatment to which they were initially assigned. Analyses were performed with the use of SAS software, version 9.2. A two-sided P value of less than 0.05 was considered to indicate statistical significance.
R e sult s
Patients
From March 2004 through March 2009, we enrolled 129 patients in the study; of these patients, 120 were included in the primary analysis (Fig. 1) . The demographic characteristics of the patients at baseline were well balanced between the two study groups (Table 1) . At baseline, 290 cutaneous squamous-cell carcinomas had been diagnosed in 120 patients; of these patients, 55% had a single lesion, and the remainder had multiple lesions (average number, 4.2; range, 2 to 15). In addition, 68% of the patients had a total of 274 other biopsy-proven skin tumors (68 basal-cell carcinomas, 27 keratoacanthomas, 90 in situ carcinomas [or Bowen's disease], and 89 premalignant keratoses). Because of empirical treatments (e.g., cryotherapy), some superficial premalignant lesions were not examined histologically, which may account for the low number of these lesions, as compared with invasive cutaneous squamous-cell carcinomas. A total of 84 patients were receiving cyclosporine, and 36 were receiving tacrolimus, with mean trough levels of 90.6±33.0 ng per milliliter and 6.9±2.2 ng per milliliter, respectively ( Table 2 in the Supplementary Appendix).
Primary End Point
Survival free of cutaneous squamous-cell carcinoma was significantly longer in the sirolimus group than in the calcineurin-inhibitor group, with a hazard ratio for new carcinoma of 0.37 (95% confidence interval [CI], 0.16 to 0.85) and a study-adjusted hazard ratio of 0.38 (95% CI, 0.17 to 0.84) ( Fig. 2A) . This difference remained significant for the patients with a single cutaneous squamouscell carcinoma (hazard ratio, 0.03; 95% CI, 0.0 to 0.91) but not for those with more than one cutaneous squamous-cell carcinoma (hazard ratio, 0.67; 95% CI, 0.29 to 1.54) (Fig. 2B and 2C ). The effect of sirolimus was not significantly different between the two studies (P = 0.054 for interaction between study and treatment group). Overall, new cutaneous squamous-cell carcinomas developed in 14 patients (22%) in the sirolimus group and in 22 (39%) in the calcineurininhibitor group (relative risk, 0.56; 95% CI, 0.32 to 0.98) after a median interval of 15 months, as compared with 7 months (P = 0.02). Among the patients in the sirolimus group who presented with new cutaneous squamous-cell carcinomas, lesions developed in 6 patients after sirolimus withdrawal, with a maximum exposure to sirolimus of 4.1 months. The sex ratio of patients with new lesions was similar to that in the initial population. The clinicopathologic characteristics of new cutaneous squamous-cell carcinomas are shown in Table 3 in the Supplementary Appendix.
Of 86 patients who completed the 2-year treatment, skin cancers that included squamous-cell carcinomas developed in 20 patients (with 71 lesions) in the sirolimus group and in 31 patients (with 191 lesions) in the calcineurin-inhibitor group (47.6% vs. 70.5%, P = 0.048). During the study period, the ratio of squamous-cell carcinoma to basal-cell carcinoma decreased from 3.9 (27 to 7) to 1.4 (11 to 8) in the sirolimus group and from 1.8 (21 to 12) to 1.0 (25 to 26) in the calcineurin-inhibitor group, as compared with the 2-year period preceding randomization.
Seven patients (including five in the sirolimus group) had a prestudy history of noncutaneous cancer; none of these patients had a relapse during the study. Six noncutaneous cancers were observed in patients with no previous history of solid-organ cancer; two lung cancers had a metastatic course (Table 2) .
No episodes of graft rejection occurred during the study (Fig. 1 in the Supplementary Appendix) . Trough levels of calcineurin inhibitors and sirolimus remained within the target range of the study (Fig. 2 in the Supplementary Appendix) . The average sirolimus levels at 9 months were not significantly higher in patients with new cutaneous squamous-cell carcinomas than those with- 
Adverse Events
Almost all sirolimus-treated patients had at least one adverse event that was considered to be related to the study drug (Table 3, and Table S4 in the Supplementary Appendix). Most such events occurred during the first 6 months of the study. A lower sirolimus dose or complementary specific treatments controlled most of them. Adverse events in the sirolimus group led to discontinuations in 15 patients (23%) after a median of 2.5 months. Overall, 37 of 64 patients were converted to sirolimus with rapid protocols; these patients had a higher rate of discontinuation than did those who were converted with progressive protocols ( Metastatic cutaneous squamous-cell carcinoma developed in one patient in the sirolimus group; this patient had received sirolimus for 2 months and was then switched back to calcineurin inhibitors. The metastasis occurred 6 months after the conversion. Eight patients in the calcineurininhibitor group were switched to sirolimus after the development of other cancers (Table 3) . Metastatic skin cancers (one case each of squamouscell carcinoma, melanoma, and Merkel-cell carcinoma) developed in three patients.
Among the 120 patients, there were 13 cutaneous squamous-cell carcinomas in 64 patients (average number, 0.20) in the sirolimus group, as compared with 39 carcinomas in 56 patients (average number, 0.70) in the calcineurin-inhibitor group. In the sirolimus group, there were 60 serious adverse events (average number, 0.94), as compared with 14 (average number, 0.25) in the calcineurin-inhibitor group (Table 3) .
Discussion
In this study of kidney-transplant recipients with at least one previous cutaneous squamous-cell carcinoma, switching from calcineurin inhibitors to sirolimus decreased the risk of new cutaneous squamous-cell carcinomas and delayed the occurrence of such lesions, as compared with continuing calcineurin inhibitors. Drug discontinuations in the sirolimus group were mainly due to the known adverse effects of the drug. 17, 22 Although serious adverse events were significantly more frequent (0.94 per patient) in the sirolimus group than in the calcineurin-inhibitor group (0.25 per patient), the number of cutaneous squamouscell carcinomas was lower by a factor of 3.4. The benefit-risk ratio appeared to increase with lower doses of sirolimus (as compared with higher doses) and with progressive conversion from calcineurin inhibitors to sirolimus (as compared with rapid conversion). This apparent antitumoral effect was more pronounced when sirolimus was introduced after the first occurrence of a cutaneous squamous-cell carcinoma, as compared with introduction after the occurrence of multiple cutaneous squamous-cell carcinomas. Furthermore, the ratio of squamous-cell carcinoma to basal-cell carcinoma decreased substantially in the sirolimus group; a decrease was also observed in the calcineurin-inhibitor group, albeit in a lower proportion of patients, possibly because of the close follow-up, which ensured the removal of premalignant lesions before they became invasive.
All metastases of skin cancers occurred in patients who were receiving calcineurin inhibitors, either initially (in three patients) or after switching back to calcineurin inhibitors after being assigned to the sirolimus group (in one patient). At baseline, the study population was representative of kidney-transplant recipients with a ratio of squamous-cell carcinoma to basal-cell carcinoma of 4. In addition, the rate of new skin cancers at 2 years in the calcineurin-inhibitor group was similar to that in previous studies. 2, 3 Although we did not observe any significant between-group difference in the rate of noncutaneous cancers, the study was inadequately powered to draw conclusions on this point. Studies that have reported a reduced cancer risk with sirolimus-based immunosuppression that was initiated at the time of transplantation or after early cyclosporine withdrawal have mainly compared regimens with two versus three immunosuppressive agents 23 or have compared outcomes with registry data. 15, 16 Furthermore, reduced rates of cancer after conversion from calcineurin inhibitors to sirolimus were driven by skin cancers rather than other cancers. 17, 18 We speculate that there may be a specific antineoplastic activity of sirolimus that explains the decrease in new skin cancers rather than a lower amount of immunosuppression. Although no standard criteria exist to compare the levels of immunosuppression of calcineurin inhibitors with those of sirolimus, trough levels were main- * Listed are all adverse events that were reported in at least 5 patients. The listed adverse events include serious adverse events. A complete list of serious adverse events (as reported in 32 patients in the sirolimus group and 11 in the calcineurin-inhibitor group) is provided in Table S4 in the Supplementary Appendix. The listed events that were deemed to be related to a study drug were edema, acnelike lesions, aphthous ulcers, proteinuria, diarrhea, dyslipidemia, pneumonitis, anemia, cough, leukopenia, exercise dyspnea, unexplained fever, rash, and thrombocytopenia. Other uncommon study-related events listed in Table S4 were delayed healing, hyperglycemia, and hypokalemia. † One patient discontinued sirolimus because of this event. ‡ Three patients discontinued sirolimus because of this event. § Seven patients discontinued sirolimus because of this event. ¶ Two patients discontinued sirolimus because of this event. ‖ Eight patients crossed over from the calcineurin-inhibitor group to receive sirolimus because of three serious adverse events (kidney cancer, lymphoma, and melanoma in one patient each) and new cutaneous squamous-cell carcinoma (in five patients).
The tained within the study targets. Moreover, equivalent doses of mycophenolate mofetil apparently induced higher drug exposure in patients treated with sirolimus than in those treated with cyclosporine. 24 Notably, we observed no events related to an overreduction in immunosuppression (mainly rejection) in the sirolimus group. The effects of mTOR inhibitors have been extensively studied in animal models and assessed in clinical studies both in patients who were not undergoing organ transplantation 25, 26 and in those with cancer. These drugs interrupt the PI3K-AKT pathway, which plays a critical role in the regulation of cell proliferation, survival, mobility, and angiogenesis. 14 Temsirolimus and everolimus are approved for the treatment of metastatic renalcell carcinoma, 27,28 although at higher doses for everolimus than for the regimens routinely administered after transplantation. 29 In addition, mTOR inhibitors also inhibit the growth of endothelial cells and the progression of tumor neovascularization at serum concentrations that correspond to the target levels for transplant recipients, both through a decrease of synthesis and a signaling inhibition of vascular endothelial growth factor. 9,14 The influence of immunosuppressive drugs on skin carcinogenesis induced by ultraviolet radiation (UV) has been assessed in mice. Larger tumors developed in animals that were treated with cyclosporine or tacrolimus than in those treated with sirolimus. 30 Furthermore, sirolimus had a better effect on the progression of UV-induced tumors than on the initiation of such tumors. 31 In transplant recipients, sirolimus has been shown to reduce the vascularization and thickness of cutaneous squamous-cell carcinomas. 32 There is also evidence to suggest that skin carcinomas might be driven by infection with human papillomavirus. 33 Since the E6 oncoprotein activates the mTOR1 pathway, 34 we speculate that sirolimus might act on skin cancer through antiviral mechanisms that have been shown with other viruses, such as cytomegalovirus [35] [36] [37] and human herpesvirus 8. 38 In conclusion, in this study involving kidneytransplant recipients with at least one previous cutaneous squamous-cell carcinoma, conversion from calcineurin inhibitors to sirolimus was associated with a lower risk of subsequent skin cancers. The data suggest that the earlier the conversion occurs after an initial diagnosis of cutaneous squamous-cell carcinoma, the greater the efficacy.
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